70 related articles for article (PubMed ID: 33619600)
61. Designs for efficient clinical trials.
Simon R
Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
[TBL] [Abstract][Full Text] [Related]
62. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.
Deandreis D; Maillard A; Zerdoud S; Bournaud C; Vija L; Sajous C; Terroir M; Leenhardt L; Schlumberger M; Borget I; Leboulleux S
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3238-3249. PubMed ID: 33619600
[TBL] [Abstract][Full Text] [Related]
63. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
[TBL] [Abstract][Full Text] [Related]
64. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
65. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
66. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract][Full Text] [Related]
67.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
68.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
69.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
70.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
